Genomics BioSci & Tech Co (TPE:4195) Research & Development: NT$85.4 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4195 Genomics BioSci & Tech Co Ltd TPE:4195
42 GF Score
Price NT$15.35
GF Value NT$34.15
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Genomics BioSci & Tech Co Research & Development?

Genomics BioSci & Tech Co TPE:4195 +0.33% 42 Research & Development is NT$85.4 Mil as of Mar. 2026. GuruFocus rates TPE:4195 with a GF Score™ of 42/100 and a GF Value™ of NT$34.15 (Possible Value Trap). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Genomics BioSci & Tech Co's Research & Development for the three months ended in Mar. 2026 was NT$20.7 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was NT$85.4 Mil.

Genomics BioSci & Tech Co  (TPE:4195) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Genomics BioSci & Tech Co Research & Development Related Terms

Genomics BioSci & Tech Co Research & Development Historical Data

* Premium members only.

The historical data trend for Genomics BioSci & Tech Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomics BioSci & Tech Co Research & Development Chart

Genomics BioSci & Tech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.47 35.88 56.43 88.50 82.50

Genomics BioSci & Tech Co Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.77 21.08 20.69 22.95 20.72
TPE:4195
42GF Score
Genomics BioSci & Tech Co Ltd TPE:4195
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomics BioSci & Tech Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$85.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$85.4 Mil mean?
Genomics BioSci & Tech Co (TPE:4195) has a Research & Development of NT$85.4 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Genomics BioSci & Tech Co and its competitors.
Is Genomics BioSci & Tech Co's Research & Development too high?
Genomics BioSci & Tech Co's current Research & Development is NT$85.4 Mil. Overall, Genomics BioSci & Tech Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genomics BioSci & Tech Co's Research & Development compare to VRTX and REGN?
Genomics BioSci & Tech Co's Research & Development of NT$85.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Genomics BioSci & Tech Co and its competitors. Genomics BioSci & Tech Co's current Research & Development is NT$85.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomics BioSci & Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Genomics BioSci & Tech Co (TPE:4195) is currently considered Possible Value Trap. The stock's GF Value™ is NT$34.15, compared to a current price of NT$15.35 — trading 55.1% below its estimated fair value. The current Research & Development is NT$85.4 Mil. Genomics BioSci & Tech Co's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Genomics BioSci & Tech Co (TPE:4195), the current Research & Development is NT$85.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomics BioSci & Tech Co (TPE:4195) Overvalued in 2026?

Based on GuruFocus' analysis, Genomics BioSci & Tech Co stock appears to be undervalued. The current stock price of NT$15.35 is trading 55.1% below its estimated GF Value™ of NT$34.15. GuruFocus considers Genomics BioSci & Tech Co to be Possible Value Trap.

Key valuation signals for TPE:4195:

  • Research & Development: NT$85.4 Mil
  • GF Value™: NT$34.15 vs. price of NT$15.35 (55.1% below fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the TPE:4195 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomics BioSci & Tech Co Business Description

Address 14th Floor, Number 100, Xintai 5th Road, Sec 1, Xizhi District, New Taipei City, Taipei, TWN
Genomics BioSci & Tech Co Ltd is a Taiwan based commercial genome sequencing company formed to develop medical genetic testing. The services of the company include Sanger sequence service, Synthesis Service and Genomic Service.
42GF Score

Get the complete analysis for TPE:4195

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.35
Price
NT$34.15
GF Value